Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
Background: Cystic fibrosis (CF) is an autosomal recessive condition leading to progressive lung disease and often necessitating lung transplantation. Historically, CF has been one of the leading indications for lung transplants in the United States. The advent of CF transmembrane conductance regula...
Saved in:
Main Authors: | Tahuanty A. Pena, MD, MS, Brittany Wright, PharmD, Kalpaj R. Parekh, MBBS, Julia Kleney-Tait, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | JHLT Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2950133424001204 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease
by: Claire Y Mou, et al.
Published: (2025-12-01) -
Prevalence and characteristics of gastrointestinal disorders, medication use, and diagnostic interventions in pediatric patients with cystic fibrosis: a nested case–control analysis from the TriNetX EMR-derived global research network real-world dataset
by: Carolena Trocchia, et al.
Published: (2025-01-01) -
Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report
by: Mohamad Hadhud, et al.
Published: (2025-01-01) -
Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
by: Hazel Ozuna, et al.
Published: (2025-01-01) -
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
by: Angela Pepe, et al.
Published: (2025-02-01)